Dambkowski Carl's Form 4 filing
Apogee Therapeutics, Inc. (APGE) · filed Sep 3, 2026
- Accession no.
- 0001140361-26-035613
- Filed
- Sep 3, 2026, 4:39 PM ET
- Trade date
- Sep 2-3, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 3 derivative transactions. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dambkowski CarlCIK 0001983476 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Common Stock | DReturned to the companyDisposed | −1,375 | $135.06 | −$185,707.5 | 167,123 | Direct | |
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −167,123 | –F1 | – | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −110,665 | –F3 | – | 0 | Direct | |
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −124,962 | –F3 | – | 0 | Direct | |
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −83,690 | –F3 | – | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
Referenced by the price of 1 transaction in Table I.
- F3
Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
Referenced by the price of 3 transactions in Table II.